Ovoca Bio (OVB) Share Price, News & Analysis

Company Overview

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

Key Stats

• Today's Range: 1.50 to 1.53
• 50-Day Range: 1.10 to 1.94
• 52-Week Range: 0.45 to 1.98
• Volume: 6,454 shs
• Average Volume: 472,904 shs
• Market Capitalization: £1.25 million
• P/E Ratio: N/A
• Dividend Yield: 0.83%
• Price Target: N/A
• Consensus Rating: N/A

OVB Stock Analysis - Frequently Asked Questions

How have OVB shares performed this year?

Ovoca Bio's stock was trading at GBX 0.90 at the beginning of 2024. Since then, OVB shares have increased by 70.0% and is now trading at GBX 1.53.
View the best growth stocks for 2024 here.

How do I buy shares of Ovoca Bio?

Shares of OVB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Ovoca Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ovoca Bio investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and J D Wetherspoon (JDW).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:OVB
• CUSIP: N/A
• CIK: N/A
• Web: www.ovocabio.com
• Phone: 353 1 661 9819
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-3,980,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -108.96%
• Return on Assets: 3.70%

Debt

• Debt-to-Equity Ratio: 4.80
• Current Ratio: 3.59
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 1.54 per share
• Price / Cash Flow: 1.00
• Book Value: GBX 2 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 81,560,000
• Free Float: N/A
• Market Cap: £1.25 million
• Optionable: Not Optionable
• Beta: 0.90